<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043376</url>
  </required_header>
  <id_info>
    <org_study_id>625/RC/KEMU/07.09.2021</org_study_id>
    <nct_id>NCT05043376</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19</brief_title>
  <official_title>A Randomized, Open-label, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Edward Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Edward Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, open-label and controlled clinical trial aimed to investigate the&#xD;
      adjuvant treatment benefits of probiotic Streptococcus salivarius K12 in hospitalised&#xD;
      mild-to-moderate patients with COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Boosting the immunity and maintaining a healthy and balanced microflora at oropharyngeal&#xD;
      environment of people through probiotics supplementation has been proposed as a possible&#xD;
      strategy to protect human host from respiratory tract infections. A slow-dissolved&#xD;
      oropharyngeal probiotic formula containing S. salivarius K12 has been clinically demonstrated&#xD;
      to improve the upper respiratory tract microbiota protecting the host from pathogenic&#xD;
      bacteria, fungi, and viruses, thereby reducing the incidence of viral respiratory tract&#xD;
      infections and bacterial co-infections. S. salivarius K12 has been proposed as a promising&#xD;
      agent for prophylactic or probiotic treatments to protect individuals during the outbreak of&#xD;
      seasonal or emerging respiratory infection diseases.&#xD;
&#xD;
      S. salivarius K12 strain, commonly known as BLIS K12, is a highly safe, and&#xD;
      extensively-studied probiotic that resides in the oral cavity. BLIS K12 has a solid&#xD;
      scienctific rationale for helping to prevent streptococcal pharyngitis and/or tonsillitis,&#xD;
      ear infections (otitis media) and to help treat halitosis. It is a specific strain of&#xD;
      Streptococcus Salivarius, which secretes powerful anti-microbial molecule called&#xD;
      Bacteriocin-Like-Inhibitory Substances (BLIS). The ingredient is believed to support healthy&#xD;
      bacteria in the mouth for long-term fresh breath and immune support.&#xD;
&#xD;
      It is proposed that the oral administration of the strain K12 to hospitalized COVID-19&#xD;
      patients (not already in ICU) receiving supplementary oxygen (not invasive oxygen theraphy)&#xD;
      to exploit the &quot;ventilation&quot; and helping S. salivarius (K12) to move from the mouth (it is an&#xD;
      oral colonizer) to the lungs, colonizing them. The idea is that the lung presence of K12&#xD;
      could strategically reduce the lung and immune capability to release pro-inflammatory&#xD;
      cytokines, thus preventing excessive lung inflammation, and the need to proceed to ICU and&#xD;
      death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>From day 1 to day 14</time_frame>
    <description>Number of patients with clinical improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation days</measure>
    <time_frame>From day 1 to day 14</time_frame>
    <description>The effect of K12 treatment in reducing the hospitalisation days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on inflammatory markers</measure>
    <time_frame>From day 1 to day 14</time_frame>
    <description>Numbers of patients with improvement in the inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU transfer</measure>
    <time_frame>From day 1 to day 14</time_frame>
    <description>Reduction in the rate of ICU transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLIS K12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard COVID-19 care as per the hospital guidelines</description>
    <arm_group_label>BLIS K12</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BLIS K12</intervention_name>
    <description>Daily 2 oral BLIS K12 tablets for up to 14 days.</description>
    <arm_group_label>BLIS K12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years (both sexes)&#xD;
&#xD;
          -  Hospitalized Confirmed (RT-PCR) COVID-19 patients (not already in ICU)&#xD;
&#xD;
          -  Patients who have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with proven hypersensitivity or allergic reaction to the tested formula&#xD;
&#xD;
          -  Patients who decline to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Somia Iqtadar, MBBS</last_name>
    <phone>+923214296189</phone>
    <email>somia.iqtadar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Edward Medical University Teaching Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Somia Iqtadar, MBBS</last_name>
      <phone>+92 321 4296189</phone>
      <email>somia.iqtadar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Edward Medical University</investigator_affiliation>
    <investigator_full_name>somia iqtadar</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

